MicroRNA-26b suppresses the NF-κB signaling and enhances the chemosensitivity of hepatocellular carcinoma cells by targeting TAK1 and TAB3
- Na Zhao†1,
- Ruizhi Wang†1,
- Liangji Zhou1,
- Ying Zhu1,
- Jiao Gong1, 2 and
- Shi-Mei Zhuang1, 2Email author
© Zhao et al.; licensee BioMed Central Ltd. 2014
Received: 30 October 2013
Accepted: 7 February 2014
Published: 24 February 2014
Abnormal activation of the NF-κB pathway is closely related to tumorigenesis and chemoresistance. Therefore, microRNAs that possess the NF-κB inhibitory activity may provide novel targets for anti-cancer therapy. miR-26 family members have been shown to be frequently downregulated in hepatocellular carcinoma (HCC) and correlated with the poor survival of HCC patients. To date, there is no report disclosing the regulatory role of miR-26 on the NF-κB pathway and its biological significance.
The effects of miR-26b on the NF-κB signaling pathway and the chemosensitivity of cancer cells were examined in two HCC cell lines, QGY-7703 and MHCC-97H, using both gain- and loss-of-function studies. The correlation between miR-26b level and apoptosis rate was further investigated in clinical HCC specimens.
Both TNFα and doxorubicin treatment activated the NF-κB signaling pathway in HCC cells. However, the restoration of miR-26b expression significantly inhibited the phosphorylation of IκBα and p65, blocked the nuclear translocation of NF-κB, reduced the NF-κB reporter activity, and consequently abrogated the expression of NF-κB target genes in TNFα or doxorubicin-treated HCC cells. Furthermore, the ectopic expression of miR-26b dramatically sensitized HCC cells to the doxorubicin-induced apoptosis, whereas the antagonism of miR-26b attenuated cell apoptosis. Consistently, the miR-26b level was positively correlated with the apoptosis rate in HCC tissues. Subsequent investigations revealed that miR-26b inhibited the expression of TAK1 and TAB3, two positive regulators of NF-κB pathway, by binding to their 3’-untranslated region. Moreover, knockdown of TAK1 or TAB3 phenocopied the effects of miR-26b overexpression.
These data suggest that miR-26b suppresses NF-κB signaling and thereby sensitized HCC cells to the doxorubicin-induced apoptosis by inhibiting the expression of TAK1 and TAB3. Our findings highlight miR-26b as a potent inhibitor of the NF-κB pathway and an attractive target for cancer treatment.
Nuclear factor κB (NF-κB) is a family of transcription factors that are implicated in many physiological and pathological processes, including immunity, inflammation, carcinogenesis and chemoresistance[1, 2]. In mammals, the NF-κB family consists of five structurally related proteins, RelA (p65), NF-κB-1 (p105/p50), NF-κB-2 (p100/p52), RelB, and c-Rel, which form various homodimers and heterodimers. The predominant form of NF-κB consists of p50 and p65 subunits. In most cell types, NF-κB is mainly trapped in the cytoplasm in an inactive form bound to IκB proteins, the inhibitors of NF-κB. In response to stimuli like tumor necrosis factor alpha (TNFα) or interleukin-1β (IL1β), TGFβ-activated kinase-1 (TAK1) and its adaptors TAB2/3 are recruited to the receptor proximal signaling complex, leading to the activation of IκB kinase (IKK). The activated IKK phosphorylates IκB proteins and triggers the ubiquitination and degradation of IκB, which allows p50/p65 heterodimer to be released, translocate to the nucleus and act as a sequence-specific DNA-binding transcription factor. Meanwhile, IKK phosphorylates the Ser536 of p65 and thereby enhances the transactivation activity of NF-κB[1, 3]. In addition to extracellular ligands that signal through membrane receptors, the chemotherapy-induced DNA damage also activates NF-κB in some cell contexts[1, 4]. Many potent anti-apoptosis genes are transactivated by NF-κB[1, 2]. Therefore, the activation of NF-κB may desensitize cells to apoptosis and thereby promote cancer progression. Unfortunately, abnormal activation of the NF-κB pathway is a common phenomenon in cancer cells.
MicroRNAs (miRNAs) are evolutionarily conserved small non-coding RNAs that suppress protein expression by binding to the 3’-untranslated region (3’UTR) of target mRNA. Several miRNAs have been reported to modify cell behavior by regulating the NF-κB pathway. For example, miR-301a, miR-30e* and miR-182 promote NF-κB activity and thereby enhance tumor growth, invasiveness or angiogenesis[5–7]. On the contrary, miR-15/16/195 and miR-146a/b have been shown to impair NF-κB activity, thus reducing the proliferation and metastasis of tumor cells[8–10]. Very few miRNAs have been characterized to affect chemosensitivity by regulating the NF-κB pathway: miR-143 sensitizes colorectal cancer cells to 5-fluorouracil treatment by downregulating ERK5, Bcl-2 and p65 expression; miR-146a enhances the chemosensitivity of NK/T cell lymphoma to etoposide by targeting TRAF6. Clearly, identification of miRNAs that target NF-κB signaling may provide novel molecular targets for cancer therapy.
It is reported that NF-κB signaling is frequently activated in hepatocellular carcinoma (HCC)[2, 13]. In order to uncover the HCC-associated miRNAs which may regulate the NF-κB pathway, we predicted the targets of those deregulated miRNAs that we found in HCC tissues, using target prediction algorithms (TargetScan). Among the miRNAs that were predicted to target the regulators of NF-κB pathway, miR-26b stood out as a potential candidate, with TAK1 and TAB3 as its putative targets. Studies from us and other groups show that the miR-26 family (miR-26a/b) is frequently downregulated in multiple types of cancer, including HCC, breast cancer, nasopharyngeal carcinoma and melanoma[15–19]. To date, there is no report disclosing the regulatory role of miR-26a/b on the NF-κB pathway and its biological significance. Because of the share of common seed sequences for target recognition, members of a miRNA family usually play similar, if not identical, roles. Therefore, we explored the impact of miR-26b on NF-κB signaling and its biological significance. We found that miR-26b suppressed the TNFα- and doxorubicin-activated NF-κB signaling in HCC cells, and sensitized cancer cells to the doxorubicin-induced apoptosis by targeting TAK1 and TAB3.
miR-26b suppresses the TNFα-induced NF-κB signaling in HCC cells
It has been demonstrated that the activated NF-κB will translocate into nucleus and induce the transcriptional activation of anti-apoptosis genes, like c-IAP1 and c-IAP2. Consistently, we observed a prominent nuclear translocation of NF-κB in the TNFα-treated NC-transfectants. However, transfection with miR-26b efficiently blocked the TNFα-induced NF-κB nuclear translocation in both QGY-7703 (Figure 1B) and MHCC-97H cells (Additional file1: Figure S1A). Furthermore, TNFα stimulation upregulated the mRNA levels of c-IAP1 and c-IAP2 in the NC-transfectants, but this effect was significantly abrogated by the transfection of miR-26b (Figure 1C and Additional file1: Figure S1B).
Collectively, these data indicate that miR-26b may suppress NF-κB signaling by attenuating the phosphorylation of IκBα and p65.
TAK1 and TAB3 are direct targets of miR-26b
As mentioned above, TAK1 and TAB3 are the upstream positive regulators of the NF-κB pathway and their 3’UTRs contain putative miR-26b-binding sites (Additional file3: Figure S3), as predicted by TargetScan (Release 5.2,http://www.targetscan.org/vert_50/, in which TAK1 and TAB3 are designated as MAP3K7 and MAP3K7IP3, respectively). We therefore examined whether TAK1 and TAB3 were direct targets of miR-26b which mediated the suppressive effect of miR-26b on NF-κB signaling.
All together, these data imply that miR-26b may repress the expression of TAK1 and TAB3 by binding to their 3’UTR and thus blocking NF-κB signaling.
miR-26b abrogates the doxorubicin-induced NF-κB activation and sensitizes HCC cells to the doxorubicin-induced apoptosis
We and others have previously shown that miR-26b is downregulated in HCC[15, 16]. To confirm the association of miR-26b with the anti-apoptosis activity of NF-κB in vivo, we further evaluated the miR-26b levels and the apoptosis rates in human HCC specimens. Linear regression analysis disclosed a significant positive correlation between the level of miR-26b and the percentage of apoptotic cells in HCC tissues (Figure 6E and Additional file6: Figure S6), suggesting that miR-26b downregulation may promote the survival of HCC cells in vivo.
NF-κB is frequently activated in the various types of tumors and promotes cancer development and chemoresistance. Therefore, miRNAs that possess the NF-κB inhibitory activity may provide novel targets for anti-cancer therapy.
The aberrant activation of NF-κB pathway may result from different causative mechanisms, like inactivating mutations or deletions of IκBα in Hodgkin’s lymphoma, activating mutations of NF-κB2 gene in B- and T-cell lymphomas, amplifications and/or translocations of NIK in multiple myeloma. In addition to the genomic aberrations of protein-coding genes, deregulation of the miRNAs that regulate the NF-κB pathway also results in the abnormal activation of the NF-κB pathway. For example, the NF-κB activators miR-301a and miR-30e* are overexpressed in pancreatic cancer and glioma, respectively[5, 6]; the NF-κB inhibitor miR-195 is downregulated in HCC. The decreased expression of the miR-26 family members has been observed in HCC tissues and the low miR-26a/b levels were associated with the short survival of patients[15, 16]. Our data reveal a significant inhibitory role of miR-26b on NF-κB signaling, suggesting miR-26b downregulation as a novel mechanism that contributes to the abnormal activation of the NF-κB pathway in HCC cells.
Doxorubicin and its analogs, like daunorubicin, have gained broad application for the chemotherapy of various malignant tumors. They trigger the apoptosis of cancer cells by interfering with the actions of DNA topoisomerase IIα and creating DNA double-strand breaks. Upon DNA damage, ataxia telangiectasia mutated (ATM) and sumoylated NF-κB essential modulator (NEMO) are jointly exported from the nucleus and mediates the TAK1/TAB2/3-dependent IKK activation. Activated IKK then induces the phosphorylation and degradation of IκBα, which further liberates NF-κB to the nucleus and stimulates its DNA-binding activity. In lymphoma and cervical cancer cells, treatment with doxorubicin/daunorubicin enhances the transactivation activity of NF-κB[24, 25]. On the other hand, although doxorubicin/daunorubicin also induces the phosphorylation and degradation of IκBα and increases the DNA-binding activity of NF-κB in osteosarcoma and breast cancer cells[26, 27], yet they repress the NF-κB reporter activity and the expression of the NF-κB-regulated anti-apoptosis genes. Histone deacetylase has been shown to be recruited to p65 in the daunorubicin-treated osteosarcoma cells, which converts p65 into an active transcription repressor of anti-apoptosis genes. In breast cancer cells, NF-κB induced by doxorubicin is deficient in phosphorylation and acetylation and represses the NF-κB-dependent transcription in a histone deacetylases-independent manner. The cellular context-dependent response calls for a cell-type-specific analysis in determining the outcome of doxorubicin-stimulated NF-κB signaling. Herein, we disclosed that doxorubicin markedly increased the level of phosphorylated p65 at the serine-536 residue and obviously activated the anti-apoptosis genes in HCC cells. Furthermore, the depletion of p65 dramatically increased the apoptosis rates of doxorubicin-exposed HCC cells, suggesting that NF-κB activation impairs the chemosensitivity of tumor cells and the inhibition of NF-κB signaling represents an effective strategy to overcome the chemoresistance of HCC to doxorubicin. Consistently, it has been shown that doxorubicin treatment activates NF-κB in other types of cancer cell lines, and blocking NF-κB activation sensitizes these cells to doxorubicin-triggered apoptosis. Importantly, we found that the restoration of miR-26b expression significantly inhibited the phosphorylation of IκBα and p65, reduced the NF-κB reporter activity, blocked the nuclear translocation of NF-κB, consequently abrogated the expression of anti-apoptosis genes and sensitized HCC cells to the doxorubicin-induced apoptosis in HCC cells. These observations indicate miR-26b as a potent NF-κB inhibitor that may increase the chemosensitivity of HCC cells.
TAK1 is a member of the mitogen-activated protein kinase kinase kinase (MAP3K) family. It mediates the activation of IKK in various cell systems. Upregulation of TAK1 is found in clear cell renal cell carcinomas and aggressive esophageal squamous cell carcinomas[29, 30]. TAB3 is markedly overexpressed in skin, testis and small intestinal cancers. Our results showed that miR-26b could decrease the protein level of TAK1 and TAB3 by directly binding to their 3’UTR. Considering that the expression of miR-26 family is frequently reduced in multiple types of cancer[15–19], we suggest that miR-26b downregulation may represent one of the mechanisms responsible for the overexpression of TAK1 and TAB3 in cancers.
In previous studies, miR-26a/b have been shown to block the G1/S transition of the cell cycle by targeting CCND2, CCNE1/2, CDK6, and EZH2 in HCC and nasopharyngeal carcinoma[15, 18, 32], and to restrain metastasis by suppressing the expression of IL6 in HCC. miR-26a/b have also been reported to induce cell apoptosis by targeting MTDH, EZH2 and SLC7A11 in breast cancer cells and by targeting SODD in melanoma cells[17, 19, 34]. Our findings suggest that miR-26b may also suppress NF-κB signaling and enhance the chemosensitivity of hepatocellular carcinoma cells by targeting TAK1 and TAB3. It is exciting to find that a single miRNA may suppress tumor growth via multiple mechanisms, which makes miR-26b a promising anti-cancer target.
In conclusion, this study demonstrated that miR-26b suppressed the TNFα- and doxorubicin-activated NF-κB signaling in HCC cells, and dramatically sensitized cancer cells to the doxorubicin-induced apoptosis. miR-26b exerted its inhibitory effect on the NF-κB pathway by repressing the expression of TAK1 and TAB3. Furthermore, the downregulation of miR-26b was correlated with the reduced apoptosis rate in HCC tissues. These findings highlight miR-26b as a potent inhibitor of the NF-κB pathway and an attractive target for cancer treatment.
Human tissue specimens
Histologically confirmed HCC tissues were collected from 20 patients who underwent HCC surgical resection at the Cancer Center of Sun Yat-sen University in Guangzhou, P.R. China. None of the patients had received any local or systemic anticancer treatment prior to the surgery. This study was approved by the Institute Research Ethics Committee at the Cancer Center and informed consent was obtained from each patient.
Cell lines and transient transfection
Human hepatocellular carcinoma cell lines QGY-7703 and MHCC-97H were maintained in Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen Corp., Buffalo, NY, USA) supplemented with 10% fetal bovine serum (FBS, Hyclone, Thermo Fisher Scientific, Victoria, Australia).
RNA oligos were reversely transfected using Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA, USA). A final concentration of 50 nM RNA duplex or 200 nM miRNA inhibitor was used. Transfection of plasmid DNA alone or together with RNA duplex was conducted using Lipofectamine 2000 (Invitrogen).
hsa-miR-26b (Pre-miR miRNA Precursor Product, cat. AM17100) and its negative control (Pre-miR Negative Control #2, cat. AM17111) were purchased from Applied Biosystems (Foster City, CA, USA). The sequence-specific miR-26b inhibitor (anti-miR-26b, cat. miR20000083) and its control (anti-NC, cat. miR02201) were obtained from Ribobio (Guangzhou, P.R. China). All siRNA duplexes were purchased from GenePharma (Shanghai, P.R. China). siTAK1, siTAB3 and sip65 targeted the mRNAs of human TAK1 [GenBank: NM_145333], TAB3 [GenBank: NM_152787] and p65 [GenBank: NM_001145138] genes, respectively. The negative control RNA duplex (siNC) for siRNA was non-homologous to any human genome sequences. The sequences of all siRNA duplexes are listed in Additional file7: Table S1.
Vectors and luciferase reporter assay
To quantitatively examine NF-κB activity, luciferase reporter plasmid containing the minimal promoter with multiple tandem NF-κB binding sites (pNF-κB-Luc, Clontech, Palo Alto, CA, USA) and its control vector (pTAL-Luc, Clontech) were employed. Cells were first reversely transfected with 50 nM RNA duplex in a 48-well plate for 24 hours, followed by co-transfection with 10 ng pRL-TK (Promega, Madison, WI, USA) and 50 ng pNF-κB-Luc or pTAL-Luc for 32 hours, then remained untreated or treated with 20 ng/ml TNFα (cat. 210-TA-010, R&D Systems, Oxon, UK) for 4 hours or doxorubicin hydrochloride (cat. D1515, Sigma-Aldrich, St. Louis, MO, USA) for 12 hours before luciferase activity analysis.
To verify the miR-26b-targeted 3’UTR, firefly luciferase reporter plasmids pGL3cm-TAK1-3’UTR-WT, pGL3cm-TAK1-3’UTR-MUT, pGL3cm-TAB3-3’UTR-WT and pGL3cm-TAB3-3’UTR-MUT were constructed. The 3’UTR segment of human TAK1 (529 bp) or TAB3 (540 bp) mRNA that contained the putative wild-type (WT) or mutant (MUT) miR-26b binding site (Additional file3: Figure S3) was PCR-amplified and inserted into the Eco RI and Xba I sites downstream of the stop codon of firefly luciferase in pGL3cm vector, which was created based upon the pGL3-control vector (Promega), as previously described. The sequences of all primers are listed in Additional file7: Table S1. Cells cultured in a 48-well plate were co-transfected with 20 nM RNA duplex, 10 ng pRL-TK and 20 ng firefly luciferase reporter containing the wild-type or mutant 3’UTR of target genes for 48 hours before luciferase activity analysis.
Luciferase activity was measured using the dual-luciferase reporter assay system (Promega). pRL-TK, which expresses Renilla luciferase, was used as an internal control to adjust for discrepancies in both transfection and harvest efficiencies. The luciferase activity of miR-26b-transfectants was normalized to the mean luciferase activity of NC-transfectants.
Immunofluorescent staining for p65
Cells cultured on coverslips in a 48-well plate, were reversely transfected with 50 nM RNA duplexes for 48 hours and remained untreated or treated with 20 ng/mL TNFα for 10 minutes. Then the cells were fixed with 4% paraformaldehyde (PFA, cat. 16005, Sigma-Aldrich) and stained with rabbit monoclonal antibody (mAb) against p65 (cat. #4764, Cell Signaling Technology, CST, Beverly, MA, USA), followed by incubation with HiLyte Fluor 555-conjugated goat anti-rabbit IgG (cat. 28176-05-H555, AnaSpec, Fremont, CA, USA) and nuclear counterstaining with DAPI (cat. D9542, Sigma-Aldrich). Fluorescent pictures were photographed with Zeiss Axio Imager Z1 (Zeiss, Jena, Germany).
RNA extraction and real-time quantitative RT-PCR
Total RNA was extracted from cultured cells using TriPure Isolation Reagent (cat. 11667165001, Roche Applied Science, Germany) according to the manufacturer’s instructions.
For real-time quantitative RT-PCR (qPCR) analysis of mRNA, 2 μg of total RNA was subjected to DNaseI digestion (Fermentas, Hanover, MD, USA) at 37°C for 30 minutes and then to heat inactivation of DNaseI at 65°C for 10 minutes, followed by reverse-transcription using Moloney murine leukemia virus reverse transcriptase (Promega). mRNA level was detected using Power SYBR® Green PCR Master Mix (Applied Biosystems) and β-actin was used as an internal control. The primers used for qPCR are listed in Additional file7: Table S1. For qPCR analysis of miRNA, cDNA was synthesized using the Taqman miRNA reverse transcription kit (Applied Biosystems). The expression levels of miR-26b and the reference gene RNU6B were quantified using the TaqMan MicroRNA Assay Kit (Applied Biosystems).
All reactions were performed on a LightCycler® 480 (Roche Diagnostics, Germany) and were run in triplicate. The cycle threshold (Ct) values did not differ by more than 0.5 among the triplicates. The levels of target genes were normalized to the levels of the internal control genes to permit the calculation of the 2-ΔΔCt value.
Cellular proteins were separated in SDS-polyacrylamide gels, electrophoretically transferred to polyvinylidene difluoride membranes (cat. #162-0177, Bio-Rad, Cambridge, MA, USA), then detected with antibodies. The sources of antibodies were as follows: mouse mAb against IκBα (cat. #4814, CST), phospho-Ser32/Ser36 of IκBα (cat. 551818, BD, Franklin Lakes, NJ, USA) and β-actin (cat. BM0627, Boster, Wuhan, China); rabbit mAb for p65 (cat. #4764, CST), phospho-Ser536 of p65 (cat. #3033, CST) and TAK1 (cat. #5206, CST); rabbit polyclonal antibodies for TAB3 (cat. ab85655, Abcam, Cambridge, MA, USA) and caspase-3 (cat. #9662, CST). β-actin was used as an internal control. All results were reproduced in three independent experiments, and the representative immunoblots are shown.
For cultured cells, 24 hours after transfection, cells were treated with doxorubicin for 48 hours, then applied to morphological examination and detection of caspase-3 activity. For morphological examination, the cells were fixed with 4% PFA, stained with DAPI and those with condensed or fragmented nuclei were considered as apoptotic cells. At least 500 cells were counted for each sample. The activity of caspase-3 was detected by immunoblotting. Activated caspase-3 resulting from the cleavage of the inactive proenzyme form was indicated as 17/19 kDa bands below the full length caspase-3 (35 kDa) band.
For HCC tissues, TUNEL staining was performed using the In Situ Cell Death Detection Kit (cat. 11684817910, Roche Applied Science), according to the manufacturer’s protocol. At least 750 cells were counted for each sample.
Data were expressed as the mean ± standard error of the mean (SEM) from at least three independent experiments. Analyses on the differences between groups were performed using GraphPad Prism version 4.0 (GraphPad Software, Inc., San Diego, CA, USA). Student’s t test was performed to compare the differences between two groups and one-way ANOVA was applied to compare more than two groups. Correlation between the miR-26b level and the apoptosis rate in HCC tissues was explored using Spearman’s correlation coefficient. All statistical tests were two-sided and P < 0.05 was considered to be statistically significant.
This study was supported by grants from Ministry of Science and Technology of China (2010CB912803, 2011CB811305), Ministry of Health of China (2012ZX10002011), National Natural Science Foundation of China (31171253) and Science and Information Technology of Guangzhou (201300000186). We are grateful to Prof. Yunfei Yuan in Dept. of Hepatobiliary Oncology, Cancer Center, Sun Yat-sen University for providing tissue specimens and the clinical information of patients.
- Perkins ND: The diverse and complex roles of NF-kappaB subunits in cancer. Nat Rev Cancer. 2012, 12: 121-132.PubMedGoogle Scholar
- Ben-Neriah Y, Karin M: Inflammation meets cancer, with NF-kappaB as the matchmaker. Nat Immunol. 2011, 12: 715-723. 10.1038/ni.2060View ArticlePubMedGoogle Scholar
- Sakurai H: Targeting of TAK1 in inflammatory disorders and cancer. Trends Pharmacol Sci. 2012, 33: 522-530. 10.1016/j.tips.2012.06.007View ArticlePubMedGoogle Scholar
- McCool KW, Miyamoto S: DNA damage-dependent NF-kappaB activation: NEMO turns nuclear signaling inside out. Immunol Rev. 2012, 246: 311-326. 10.1111/j.1600-065X.2012.01101.xPubMed CentralView ArticlePubMedGoogle Scholar
- Lu Z, Li Y, Takwi A, Li B, Zhang J, Conklin DJ, Young KH, Martin R, Li Y: miR-301a as an NF-kappaB activator in pancreatic cancer cells. EMBO J. 2011, 30: 57-67. 10.1038/emboj.2010.296PubMed CentralView ArticlePubMedGoogle Scholar
- Jiang L, Lin C, Song L, Wu J, Chen B, Ying Z, Fang L, Yan X, He M, Li J, Li M: MicroRNA-30e* promotes human glioma cell invasiveness in an orthotopic xenotransplantation model by disrupting the NF-kappaB/IkappaBalpha negative feedback loop. J Clin Invest. 2012, 122: 33-47. 10.1172/JCI58849PubMed CentralView ArticlePubMedGoogle Scholar
- Song L, Liu L, Wu Z, Li Y, Ying Z, Lin C, Wu J, Hu B, Cheng SY, Li M, Li J: TGF-beta induces miR-182 to sustain NF-kappaB activation in glioma subsets. J Clin Invest. 2012, 122: 3563-3578. 10.1172/JCI62339PubMed CentralView ArticlePubMedGoogle Scholar
- Roccaro AM, Sacco A, Thompson B, Leleu X, Azab AK, Azab F, Runnels J, Jia X, Ngo HT, Melhem MR, Lin CP, Ribatti D, Rollins BJ, Witzig TE, Anderson KC, Ghobrial IM: MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood. 2009, 113: 6669-6680. 10.1182/blood-2009-01-198408PubMed CentralView ArticlePubMedGoogle Scholar
- Ding J, Huang S, Wang Y, Tian Q, Zha R, Shi H, Wang Q, Ge C, Chen T, Zhao Y, Liang L, Li J, He X: Genome-wide screening reveals that miR-195 targets the TNF-alpha/NF-kappaB pathway by down-regulating IkappaB kinase alpha and TAB3 in hepatocellular carcinoma. Hepatology. 2013, 58: 654-666. 10.1002/hep.26378View ArticlePubMedGoogle Scholar
- Bhaumik D, Scott GK, Schokrpur S, Patil CK, Campisi J, Benz CC: Expression of microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in breast cancer cells. Oncogene. 2008, 27: 5643-5647. 10.1038/onc.2008.171PubMed CentralView ArticlePubMedGoogle Scholar
- Borralho PM, Kren BT, Castro RE, da Silva IB, Steer CJ, Rodrigues CM: MicroRNA-143 reduces viability and increases sensitivity to 5-fluorouracil in HCT116 human colorectal cancer cells. FEBS J. 2009, 276: 6689-6700. 10.1111/j.1742-4658.2009.07383.xView ArticlePubMedGoogle Scholar
- Paik JH, Jang JY, Jeon YK, Kim WY, Kim TM, Heo DS, Kim CW: MicroRNA-146a downregulates NFkappaB activity via targeting TRAF6 and functions as a tumor suppressor having strong prognostic implications in NK/T cell lymphoma. Clin Cancer Res. 2011, 17: 4761-4771. 10.1158/1078-0432.CCR-11-0494View ArticlePubMedGoogle Scholar
- Liu P, Kimmoun E, Legrand A, Sauvanet A, Degott C, Lardeux B, Bernuau D: Activation of NF-kappa B, AP-1 and STAT transcription factors is a frequent and early event in human hepatocellular carcinomas. J Hepatol. 2002, 37: 63-71. 10.1016/S0168-8278(02)00064-8View ArticlePubMedGoogle Scholar
- Su H, Yang JR, Xu T, Huang J, Xu L, Yuan Y, Zhuang SM: MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res. 2009, 69: 1135-1142.View ArticlePubMedGoogle Scholar
- Zhu Y, Lu Y, Zhang Q, Liu JJ, Li TJ, Yang JR, Zeng C, Zhuang SM: MicroRNA-26a/b and their host genes cooperate to inhibit the G1/S transition by activating the pRb protein. Nucleic Acids Res. 2012, 40: 4615-4625. 10.1093/nar/gkr1278PubMed CentralView ArticlePubMedGoogle Scholar
- Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, Ambs S, Chen Y, Meltzer PS, Croce CM, Qin LX, Man K, Lo CM, Lee J, Ng IO, Fan J, Tang ZY, Sun HC, Wang XW: MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med. 2009, 361: 1437-1447. 10.1056/NEJMoa0901282PubMed CentralView ArticlePubMedGoogle Scholar
- Zhang B, Liu XX, He JR, Zhou CX, Guo M, He M, Li MF, Chen GQ, Zhao Q: Pathologically decreased miR-26a antagonizes apoptosis and facilitates carcinogenesis by targeting MTDH and EZH2 in breast cancer. Carcinogenesis. 2011, 32: 2-9. 10.1093/carcin/bgq209View ArticlePubMedGoogle Scholar
- Lu J, He ML, Wang L, Chen Y, Liu X, Dong Q, Chen YC, Peng Y, Yao KT, Kung HF, Li XP: MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. Cancer Res. 2011, 71: 225-233. 10.1158/0008-5472.CAN-10-1850View ArticlePubMedGoogle Scholar
- Reuland SN, Smith SM, Bemis LT, Goldstein NB, Almeida AR, Partyka KA, Marquez VE, Zhang Q, Norris DA, Shellman YG: MicroRNA-26a is strongly downregulated in melanoma and induces cell death through repression of silencer of death domains (SODD). J Invest Dermatol. 2013, 133: 1286-1293. 10.1038/jid.2012.400PubMed CentralView ArticlePubMedGoogle Scholar
- Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS: NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science. 1998, 281: 1680-1683.View ArticlePubMedGoogle Scholar
- Tacar O, Sriamornsak P, Dass CR: Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol. 2013, 65: 157-170. 10.1111/j.2042-7158.2012.01567.xView ArticlePubMedGoogle Scholar
- Notarbartolo M, Poma P, Perri D, Dusonchet L, Cervello M, D'Alessandro N: Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells. Analysis of their possible relationship to changes in NF-kB activation levels and in IAP gene expression. Cancer Lett. 2005, 224: 53-65. 10.1016/j.canlet.2004.10.051View ArticlePubMedGoogle Scholar
- Staudt LM: Oncogenic activation of NF-kappaB. Cold Spring Harb Perspect Biol. 2010, 2: a000109PubMed CentralView ArticlePubMedGoogle Scholar
- Boland MP: Daunorubicin Activates NFkappa B and Induces kappa B-dependent Gene Expression in HL-60 Promyelocytic and Jurkat T Lymphoma Cells. J Biol Chem. 1997, 272: 12952-12960. 10.1074/jbc.272.20.12952View ArticlePubMedGoogle Scholar
- Bottero V, Busuttil V, Loubat A, Magne N, Fischel JL, Milano G, Peyron JF: Activation of nuclear factor kappaB through the IKK complex by the topoisomerase poisons SN38 and doxorubicin: a brake to apoptosis in HeLa human carcinoma cells. Cancer Res. 2001, 61: 7785-7791.PubMedGoogle Scholar
- Campbell KJ, Rocha S, Perkins ND: Active repression of antiapoptotic gene expression by RelA(p65) NF-kappa B. Mol Cell. 2004, 13: 853-865. 10.1016/S1097-2765(04)00131-5View ArticlePubMedGoogle Scholar
- Ho WC, Dickson KM, Barker PA: Nuclear factor-kappaB induced by doxorubicin is deficient in phosphorylation and acetylation and represses nuclear factor-kappaB-dependent transcription in cancer cells. Cancer Res. 2005, 65: 4273-4281. 10.1158/0008-5472.CAN-04-3494View ArticlePubMedGoogle Scholar
- Li F, Sethi G: Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy. Biochim Biophys Acta. 1805, 2010: 167-180.Google Scholar
- Wen J, Hu Y, Luo KJ, Yang H, Zhang SS, Fu JH: Positive transforming growth factor-beta activated kinase-1 expression has an unfavorable impact on survival in T3N1-3 M0 esophageal squamous cell carcinomas. Ann Thorac Surg. 2013, 95: 285-290. 10.1016/j.athoracsur.2012.09.050View ArticlePubMedGoogle Scholar
- Wei C, Lai Y-Q, Li X-X, Ye J-X: TGF-β-activated kinase-1: a potential prognostic marker for clear cell renal cell carcinoma. Asian Pacific J Cancer Prev. 2013, 14: 315-320. 10.7314/APJCP.2013.14.1.315.View ArticleGoogle Scholar
- Jin G, Klika A, Callahan M, Faga B, Danzig J, Jiang Z, Li X, Stark GR, Harrington J, Sherf B: Identification of a human NF-kappaB-activating protein, TAB3. Proc Natl Acad Sci USA. 2004, 101: 2028-2033. 10.1073/pnas.0307314101PubMed CentralView ArticlePubMedGoogle Scholar
- Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, Hwang HW, Chang TC, Vivekanandan P, Torbenson M, Clark KR, Mendell JR, Mendell JT: Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell. 2009, 137: 1005-1017. 10.1016/j.cell.2009.04.021PubMed CentralView ArticlePubMedGoogle Scholar
- Yang X, Liang L, Zhang XF, Jia HL, Qin Y, Zhu XC, Gao XM, Qiao P, Zheng Y, Sheng YY, Wei JW, Zhou HJ, Ren N, Ye QH, Dong QZ, Qin LX: MicroRNA-26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting interleukin-6-Stat3 pathway. Hepatology. 2013, 58: 158-170. 10.1002/hep.26305View ArticlePubMedGoogle Scholar
- Liu XX, Li XJ, Zhang B, Liang YJ, Zhou CX, Cao DX, He M, Chen GQ, He JR, Zhao Q: MicroRNA-26b is underexpressed in human breast cancer and induces cell apoptosis by targeting SLC7A11. FEBS Lett. 2011, 585: 1363-1367. 10.1016/j.febslet.2011.04.018View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.